1. Search Result
Search Result
Results for "

SIRT

" in MedChemExpress (MCE) Product Catalog:

207

Inhibitors & Agonists

2

Fluorescent Dye

3

Biochemical Assay Reagents

2

Peptides

36

Natural
Products

10

Recombinant Proteins

9

Isotope-Labeled Compounds

7

Antibodies

1

Click Chemistry

19

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133998
    SIRT-IN-3
    1 Publications Verification

    Sirtuin Cancer
    SIRT-IN-3 is a potent SIRT inhibitor, with an IC50 of 17 μM for SIRT1. SIRT-IN-3 shows about 4-fold and 14-fold selectivity for SIRT1 over SIRT2 and SIRT3, respectively (IC50 of 74 μM and 235 μM for SIRT2 and SIRT3, respectively) .
    SIRT-IN-3
  • HY-136199
    SIRT1-IN-1
    1 Publications Verification

    Sirtuin CMV Infection
    SIRT1-IN-1 is a selective SIRT1 inhibitor with an IC50 of 0.205 μM. SIRT1-IN-1 inhibits SIRT2 with an IC50 of 11.5 μM . SIRT1-IN-1, a indole, is a cytomegalovirus (CMV) inhibitors and has antiviral activity .
    SIRT1-IN-1
  • HY-103721

    Sirtuin Cancer
    SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
    SIRT6-IN-2
  • HY-107660

    Sirtuin Neurological Disease
    SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .
    SIRT2-IN-8
  • HY-169934

    Sirtuin Cancer
    SIRT1-IN-4 (Compound 8c) is a SIRT1 inhibitor, with an IC50 of 10.04 μM. SIRT1-IN-4 can be used for the research of cancer .
    SIRT1-IN-4
  • HY-W109401

    Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with IC50 values of >50 μM. SIRT-IN-6 is promising for research of metabolic, inflammatory, oncologic and neurodegenerative disorders .
    SIRT-IN-6
  • HY-172204

    Sirtuin Apoptosis Autophagy MDM-2/p53 Cancer
    SIRT-IN-7 (Compound 7ba) is a SIRT inhibitor. SIRT-IN-7 can inhibit the expression of SIRT1, SIRT2, and SIRT3, and increase the acetylation and activation of p53. SIRT-IN-7 can inhibit the proliferation, and induce apoptosis and autophagy of breast cancer cells. SIRT-IN-7 has anti-tumor activity .
    SIRT-IN-7
  • HY-151185

    Sirtuin Cancer
    Sirt2-IN-7 (compound 22) is a selective inhibitor of SIRT2. Sirt2-IN-7 inhibits SIRT2 with an IC50 value and a Ki value of 178.2 nM and 154.3 nM, respectively. Sirt2-IN-7 can be used for the research of cancer .
    Sirt2-IN-7
  • HY-118109

    Sirtuin
    SIRT3-IN-2 (Inhibitor scaffolds in Scheme 1) is a SIRT3 inhibitor, reducing SIRT3 activity by 39% at a concentration of 200 µM. SIRT3-IN-2 is promising for research into metabolic homeostasis and tumor suppression .
    SIRT3-IN-2
  • HY-115979

    Sirtuin Neurological Disease Cancer
    Sirt2-IN-5 is a potent SIRT2 inhibtor .
    Sirt2-IN-5
  • HY-145958

    Sirtuin Cancer
    Sirt2-IN-6 (compound 24a) potent and selective inhibitor of SIRT2, with an IC50 of 0.815 μM. Sirt2-IN-6 can be used for the research of cancer .
    Sirt2-IN-6
  • HY-16615

    Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 μM, respectively.
    SIRT-IN-1
  • HY-16616

    Sirtuin Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SIRT-IN-2 is a potent inhibitor of SIRT1/2/3, with IC50s of 4, 4, 7 μM, respectively.
    SIRT-IN-2
  • HY-151522

    Sirtuin Neurological Disease Cancer
    SIRT2-IN-10 (Compound 12) is a potent SIRT2 inhibitor with an IC50 of 1.3 μM. SIRT2-IN-10 can be used for the research of cancer and neurodegenerative disease .
    SIRT2-IN-10
  • HY-161920

    Sirtuin Apoptosis Cancer
    SIRT3-IN-1 (compound 17f) is a SIRT3 inhibitor, with IC50 of 0.043 μM. SIRT3-IN-1 can be used in the research of acute leukemia (AML) .
    SIRT3-IN-1
  • HY-156027

    Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-163698

    Sirtuin Cancer
    SIRT-IN-4 is an inhibitor of the NAD+-dependent lysine deacetylase Sirtuin2 (Sirt2) (IC50=0.35 μM). SIRT-IN-4 is a potent Sirt2 deacetylase inhibitor that reduces cell survival and inhibits the migration of prostate cancer cells. SIRT-IN-4 can be used to study Sirt2 in cell cycle regulation, gene expression regulation, etc .
    SIRT-IN-4
  • HY-170578

    Sirtuin Neurological Disease
    SIRT2-IN-17 (compound Z18) is a potent SIRT2 inhibitor. SIRT2-IN-17 reduces the expression of α-SMA and p-Smad2/3 .
    SIRT2-IN-17
  • HY-146013

    Sirtuin Microtubule/Tubulin Cancer
    Sirt1/2-IN-1 (Compound 7) is a SIRT1 and SIRT2 inhibitor with IC50 values of 1.81, 2.10 and 20.5 µg/mL against SIRT1, SIRT2 and SIRT3, respectively. Sirt1/2-IN-1 displays activity in hyperacetylation of α-tubulin protein with an IC50 of 32.05 µg/mL. Sirt1/2-IN-1 shows prominent anticancer activity .
    Sirt1/2-IN-1
  • HY-170402

    Sirtuin Apoptosis Cancer
    SIRT6-IN-4 (Compound 10d) is a selective inhibitor for SIRT6 with an IC50 of 5.68 μM. SIRT6-IN-4 inhibits the proliferation of MCF-7 with an IC50 of 8.30 μM. SIRT6-IN-4 arrests the cell cycle at G2/M phase, inhibits thecell migration and invasion of MCF-7, and induces apoptosis. SIRT6-IN-4 exhibits antitumor efficacy in mouse models .
    SIRT6-IN-4
  • HY-161339

    Apoptosis Sirtuin Cancer
    SIRT2-IN-13 (compound 7c) is an inhibitor of SIRT2 and induces apoptosis. SIRT2-IN-13 selectively inhibits colon cancer and leukemia cells and arrests the cell cycle in the G2 phase .
    SIRT2-IN-13
  • HY-151519

    Sirtuin Cancer
    SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer .
    SIRT2-IN-9
  • HY-155729

    Sirtuin Apoptosis Cancer
    Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC50s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity .
    Sirt1/2-IN-4
  • HY-123194

    Histone Demethylase Sirtuin Metabolic Disease
    SIRT2/6-IN-1 (Compound 5) is a SIRT6/SIRT2 inhibitor, with IC50s of 106 μM and 114 μM. SIRT2/6-IN-1 increases H3K9 acetylation, increases glucose uptake and reduces TNF-α secretion in cells .
    SIRT2/6-IN-1
  • HY-148408

    Sirtuin Cancer
    SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers .
    SIRT2-IN-11
  • HY-162252

    Sirtuin Others
    SIRT2-IN-12 (Compound 3) is a SIRT2 inhibitor with a IC50 value of 50 μM .
    SIRT2-IN-12
  • HY-112427

    Sirtuin Inflammation/Immunology Cancer
    Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC50 of 163 nM .
    Sirt2-IN-1
  • HY-112428

    Sirtuin Inflammation/Immunology
    Sirt2-IN-2 (Compound 10) is a selective Sirt2 inhibitor with an IC50 of 0.118 μM .
    Sirt2-IN-2
  • HY-160617

    Sirtuin Neurological Disease
    SIRT2-IN-14 (Compound 78) is a selectve inhibitor for SIRT2 with an IC50 of 0.196 μM .
    SIRT2-IN-14
  • HY-155728

    Sirtuin Apoptosis Cancer
    Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC50s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .
    Sirt1/2-IN-3
  • HY-155727

    Sirtuin Apoptosis Cancer
    Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC50s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respsectivley. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines .
    Sirt1/2-IN-2
  • HY-148712

    Apoptosis Sirtuin Cancer
    SIRT6 activator 12q is potent, selective and orally active SIRT6 activator with IC50 values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity .
    SIRT6 activator 12q
  • HY-163316

    Sirtuin Metabolic Disease Cancer
    SIRT4-IN-1 (compound 69) is selective sirtuin 4 (Sirt4) inhibitor with an IC50 of 16 μM.SIRT4-IN-1 shows no relevant effects on other sirtuin isoforms .
    SIRT4-IN-1
  • HY-159126

    Sirtuin Neurological Disease
    SIRT2-IN-15 (compound 1) is a SIRT2 deacetylase and deamyloacylase inhibitor with IC50 7 and 37 μM, respectively .
    SIRT2-IN-15
  • HY-146690

    Sirtuin Cancer
    SIRT1-IN-3 (compound 3j) is a potent and selective SIRT1 inhibitor, with an IC50 of 4.2 μM .
    SIRT1-IN-3
  • HY-146689

    Sirtuin Cancer
    SIRT1-IN-2 (compound 3h) is a potent and selective SIRT1 (silent information regulator 1) inhibitor, with an IC50 of 1.6 μM .
    SIRT1-IN-2
  • HY-114906

    Sirtuin Cancer
    SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma .
    SIRT1/2/3-IN-2
  • HY-169051

    Sirtuin Cancer
    SIRT-IN-5 is a SIRT3 inhibitor, with an IC50 value of 2.88 μM. SIRT-IN-5 can promote the differentiation of multiple myeloma cells, along with an increase in the expression of the differentiation antigen CD49e and human immunoglobulin light chains λ and κ .
    SIRT-IN-5
  • HY-146386

    Sirtuin Neurological Disease Cancer
    SIRT5 inhibitor 2 (compound 49) is a potent SIRT5 inhibitor with an IC50 value of 2.3 μM. SIRT5 inhibitor 2 has inhibitory activity against the SIRT5-dependent desuccinylation. SIRT5 inhibitor 2 can be used for researching cancer and neurodegenerative diseases .
    SIRT5 inhibitor 2
  • HY-150727

    Sirtuin Cancer
    SIRT5 inhibitor 4 (compound 11) is a potent, selective SIRT5 inhibitor with IC50 values of 26.4 and >400μM for SIRT5 and other SIRT subtype, respectively .
    SIRT5 inhibitor 4
  • HY-169809

    Sirtuin Cancer
    SIRT1-IN-5 (215) is a NAD-dependent protein deacetylase sirtuin-1 modulator .
    SIRT1-IN-5
  • HY-146387

    Sirtuin Neurological Disease Cancer
    SIRT5 inhibitor 3 (compound 46) is a potent and competitive SIRT5 inhibitor with an IC50 value of 5.9 μM. SIRT5 inhibitor 3 can inhibit SIRT5 desuccinylation. SIRT5 inhibitor 3 can be used for researching cancer and neurodegenerative diseases .
    SIRT5 inhibitor 3
  • HY-163987

    Sirtuin Neurological Disease
    SIRT3 activator 2 (compound 2a) is a SIRT3 activator. SIRT3 activator 2 improved the thermal stability of SIRT3 in SH-SY5Y cells, indicating that it can directly bind to SIRT3, has SIRT3 dependency in SH-SY5Y to clear α-Syn. SIRT3 activator 2 improves motor function in Parkinson mice, preventing Parkinson (DA) neuron loss in the substantia nigra in a dose-dependent manner .
    SIRT3 activator 2
  • HY-135899
    SIRT7 inhibitor 97491
    3 Publications Verification

    Sirtuin Apoptosis Cancer
    SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. .
    SIRT7 inhibitor 97491
  • HY-158162

    Sirtuin Cardiovascular Disease
    SIRT3 activator 1 (Compound 5v) is a SIRT3 activator. SIRT3 activator 1 selectively elevates SIRT3 expression, leading to the upregulation of SOD2 and OPA1 expression, effectively preventing mitochondrial dysfunction, mitigating oxidative stress, and preserving cardiomyocyte viability. SIRT3 activator 1 can be used for research of cardiovascular diseases .
    SIRT3 activator 1
  • HY-111317

    Sirtuin Metabolic Disease
    SIRT1 activator 3 is a potent activator of Sirt1 and suppresses TNF-α in a dose-dependent manner. SIRT1 activator 3 has the potential for anti-obesity or anti-diabetic researches .
    SIRT1 activator 3
  • HY-149425

    Sirtuin Inflammation/Immunology Cancer
    SIRT5 Inhibitor 6 is a potent, substrate-competitive and selective SIRT5 inhibitor with an IC50 of 3.0 μM. SIRT5 Inhibitor6 has a therapeutic potential against septic AKI in vivo .
    SIRT5 inhibitor 6
  • HY-152214

    Sirtuin Cancer
    SIRT5 inhibitor 5 is a potent SIRT5 inhibitor with an IC50 value of 0.21 µM. SIRT5 inhibitor 5 does not occupy the NNAD + -binding pocket and acts as a substrate-competitive inhibitor .
    SIRT5 inhibitor 5
  • HY-N12386

    Sirtuin Cancer
    SIRT1 activator 1(compound 3) is a derivative of marine compound xyloallenoide A isolated from the mangrove fungus Xylaria sp.SIRT1 activator 1 shows angiogenic activities in zebrafish. SIRT1 activator 1 protects hEPC against AngII-induced senescence by increasing SIRT1 expression levels and balancing the AMPK/Akt signaling pathway .
    SIRT1 activator 1
  • HY-149524

    Sirtuin Cancer
    SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor (IC50: 5.38 μM) of sirtuin SIRT5 with anticancer potential .
    SIRT5 inhibitor 8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: